Epilepsy has many etiologies including structural, metabolic, genetic and unidentified causes. Recently, autoimmune mechanisms found to be the cause of some of them. Here we present a19 years-old female who present with Status Epilepticus (SE).
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19 years old female presents with confusion and personality changes with 4 days of duration. At the end of the 4th day she had 4 consecutive generalized tonic clonic seizures and admitted to our emergency clinic. In the first neurological evaluation she was unconscious with no motor impairment. She had a history of upper respiratory tract infection (URTI) associated with low-grade fever in the previous week. She had given phenytoin and levetiracetam intravenous infusion in order to treat SE. Extensive laboratory examination including cerebrospinal fluid revealed no cause of SE. EEG shows generalized slowing and waxing and waning pattern of periodic lateralized epileptiform discharges mostly localized on the right parietotemporal area. On the 5th day of her admission, she transferred to the ICU for intravenous midazolam infusion. There is no change either in her mental status or EEG, after 3 days of midazolam infusion. We decided to make plasma exchange (PLEX) for Refractory SE (RSE) treatment. After completion of the2nd PLEX both consciousness level and EEG improved.
Autoimmunity was the suspected etiology in our case because she had a history URTI, low-grade fever and very good response to PLEX. PLEX should come to our mind in RSE cases especially with suspected autoimmune etiology. Background: Epilepsy is a common chronic neurological condition that is characterized by recurrent unprovoked seizures. A synonymous C to T variant at position 3435 (3435C N T) is one common polymorphism of the multidrug resistant 1 (MDR1) gene, which encodes the major transmembrane efflux transporter P-glycoprotein and form an important class of proteins for regulating pharmacokinetics. Phenytoin, a widely used anti-epileptic drug, exhibits marked inter-individual variation in Pharmacokinetics and attributed to genetic factors such as MDR1 polymorphism. Objective: The present study was undertaken to investigate the influence of MDR1 variant genotypes on Phenytoin Pharmacokinetics in the epileptic patients from Saudi Arabia. Material and methods: 25 epileptic individuals with non-responders to phenytoin monotherapy and 25 epileptic subjects with responders to phenytoin monotherapy were recruited after getting their informed consent and genotyped for MDR1 (3435C N T) polymorphisms by Polymerase chain reaction-restriction fragment length polymorphisms (PCR-RFLP Method). Allele frequencies were derived from genotypic data Phenytoin plasma levels were analyzed by reverse phase HPLC method and Pharmacokinetic parameters were estimated by non-compartmental analysis using PK solutions software. Results: The MDR1 (3435C N T) polymorphism was seen to be in Hardy-Weinberg equilibrium and showed significant allelic association and genotypic association between non responders and responders to phenytoin (P b 0.01). The pharmacokinetics parameters in homozygous mutant group showed longer half-life (t1/ 2 = 33.26 hrs) and less clearance rate (CL = 0.42 L/hr) when compared to wild type group (t 1/2 = 19.2 hrs, CL = 0.8 L/hr). This study aimed to estimate the prevalence and underdiagnosis of depression in patients with epilepsy, identifying possible association between type, etiology and medications. It is a cross-sectional study by
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